Systemic immune response invoked by short-course oxaliplatin-based chemotherapy (FLOX) for efficacy of sequential immune checkpoint blockade (ICB; nivolumab) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Meltzer, Sebastian
Flatmark, Kjersti
Fuglestad, Anniken J.
Hamre, Hanne M.
Kersten, Christian
Hofsli, Eva
Guren, Marianne G.
Sorbye, Halfdan
Negard, Anne
Ree, Anne Hansen
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3279
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3279
引用
下载
收藏
页数：3
相关论文
共 17 条
  • [1] Early radiologic signal of nivolumab responsiveness after short-course oxaliplatin-based chemotherapy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
    Meltzer, Sebastian
    Negard, Anne
    Hamre, Hanne Mari
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne Gronlie
    Sorbye, Halfdan
    Flatmark, Kjersti
    Ree, Anne Hansen
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
    Meltzer, S.
    Berg, J. P.
    Hamre, H. M.
    Kersten, C.
    Hofsli, E.
    Guren, M. G.
    Sorbye, H.
    Flatmark, K.
    Ree, A. H.
    ANNALS OF ONCOLOGY, 2023, 34 : S449 - S449
  • [3] Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.
    Ree, Anne Hansen
    Hamre, Hanne
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne Gronlie
    Sorbye, Halfdan
    Johansen, Christin
    Negard, Anne
    Flatmark, Kjersti
    Meltzer, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
    Ree, Anne Hansen
    Hoye, Eirik
    Esbensen, Ying
    Beitnes, Ann-Christin R.
    Negard, Anne
    Bernklev, Linn
    Tetlie, Linn Kruse
    Fretland, Asmund A.
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Nilsen, Hilde L.
    Flatmark, Kjersti
    Meltzer, Sebastian
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [5] Immunogenic chemotherapy and immune checkpoint inhibition (ICI) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Biomarkers indicative of durable treatment response.
    Ree, Anne Hansen
    Meltzer, Sebastian
    Bakke, Kine M.
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne Gronlie
    Sorbye, Halfdan
    Johansen, Christin
    Negard, Anne
    Redalen, Kathrine Roe
    Flatmark, Kjersti
    CANCER RESEARCH, 2021, 81 (13)
  • [6] Alternating short-course oxaliplatin-based chemotherapy and nivolumab as first-line treatment of patients with abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC): A randomized phase 2 trial
    Ree, Anne Hansen
    Benth, Jurate Saltyte
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Johansen, Christin
    Negard, Anne
    Esbensen, Ying
    Bjornetro, Tonje
    Juul, Hedvig V.
    Kaveh, Fatemeh
    Inderberg, Else Marit
    Nilsen, Hilde Loge
    Flatmark, Kjersti
    Meltzer, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Immune dynamics and response predictors to regorafenib, ipilimumab, and nivolumab (RIN) treatment in chemotherapy resistant microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Ye, Jian
    Wang, Chongkai
    Egelston, Colt
    Guo, Weihua
    Lee, Peter
    Fakih, Marwan
    CANCER RESEARCH, 2024, 84 (06)
  • [8] First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial
    Ree, Anne Hansen
    Benth, Jurate Saltyte
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Johansen, Christin
    Negard, Anne
    Bjornetro, Tonje
    Nilsen, Hilde L.
    Berg, Jens P.
    Flatmark, Kjersti
    Meltzer, Sebastian
    BRITISH JOURNAL OF CANCER, 2024, 130 (12) : 1921 - 1928
  • [9] Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatinbased chemotherapy and immune checkpoint blockade (ICB)
    Ree, Anne Hansen
    Bousquet, Paula A.
    Nilsen, Hilde L.
    Luders, Torben
    Wang, Shixiong
    Visnovska, Tina
    Bordin, Diana L.
    Hoye, Eirik
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Flatmark, Kjersti
    Meltzer, Sebastian
    CANCER RESEARCH, 2024, 84 (06)
  • [10] Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-9
    Lee, James J.
    Yothers, Greg
    George, Thomas J.
    Fakih, Marwan G.
    Mallick, Atrayee Basu
    Mitchell, Edith P.
    Wade, James L.
    Krauss, John C.
    Kayaleh, Omar R.
    Heron, Dwight E.
    Allegra, Carmen J.
    Lipchik, Corey
    Feng, Huichen
    Joy, Marion
    Srinivasan, Ashok
    Pogue-Geile, Katherine L.
    Lucas, Peter C.
    Warren, Sarah E.
    Cesano, Alessandra
    Jacobs, Samuel A.
    CANCER RESEARCH, 2019, 79 (13)
12